Your browser is no longer supported. Please, upgrade your browser.
Settings
PAND [NASD]
Pandion Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own25.48% Shs Outstand23.28M Perf Week143.85%
Market Cap1.80B Forward P/E- EPS next Y-1.54 Insider Trans3.13% Shs Float22.00M Perf Month240.17%
Income- PEG- EPS next Q-0.38 Inst Own46.90% Short Float2.20% Perf Quarter254.34%
Sales7.56M P/S237.71 EPS this Y-95.60% Inst Trans-0.18% Short Ratio1.63 Perf Half Y234.96%
Book/sh9.66 P/B6.34 EPS next Y26.30% ROA- Target Price42.50 Perf Year-
Cash/sh7.92 P/C7.73 EPS next 5Y- ROE- 52W Range10.28 - 61.23 Perf YTD312.32%
Dividend- P/FCF- EPS past 5Y- ROI56.50% 52W High0.00% Beta-
Dividend %- Quick Ratio20.30 Sales past 5Y- Gross Margin- 52W Low495.62% ATR3.56
Employees43 Current Ratio20.30 Sales Q/Q- Oper. Margin- RSI (14)94.94 Volatility2.89% 7.81%
OptionableNo Debt/Eq0.00 EPS Q/Q-100.30% Profit Margin- Rel Volume1.23 Prev Close61.19
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume296.58K Price61.23
Recom2.50 SMA20129.84% SMA50190.74% SMA200256.38% Volume358,845 Change0.07%
Aug-11-20Initiated SVB Leerink Outperform $24
Aug-11-20Initiated Morgan Stanley Overweight $25
Aug-11-20Initiated Goldman Buy $28
Aug-10-20Initiated BMO Capital Markets Outperform $29
Mar-01-21 11:02PM  
07:34PM  
08:00AM  
Feb-27-21 01:42AM  
Feb-26-21 10:49AM  
10:06AM  
10:04AM  
02:23AM  
Feb-25-21 09:51PM  
07:03PM  
06:00PM  
04:30PM  
03:05PM  
01:00PM  
11:49AM  
11:33AM  
10:50AM  
10:48AM  
07:43AM  
07:06AM  
06:45AM  
05:53AM  
Feb-22-21 08:30AM  
03:07AM  
Feb-18-21 08:30AM  
Jan-04-21 04:28PM  
08:00AM  
Dec-12-20 11:05PM  
Dec-03-20 08:00AM  
Nov-23-20 12:40AM  
Nov-16-20 04:01PM  
Nov-10-20 08:00AM  
Oct-31-20 08:00AM  
Oct-28-20 08:00AM  
Oct-20-20 11:57AM  
Sep-24-20 08:00AM  
Sep-10-20 08:00AM  
Aug-31-20 04:05PM  
Aug-23-20 11:33AM  
Aug-16-20 08:59AM  
Aug-07-20 08:15PM  
Jul-17-20 12:03PM  
08:46AM  
Jul-16-20 06:20AM  
Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Becker Daniel J.DirectorNov 19Buy15.12197,7162,989,4662,827,883Nov 23 05:30 PM
Becker Daniel J.DirectorNov 18Buy15.2614,197216,6462,630,167Nov 19 08:15 PM
Becker Daniel J.DirectorNov 17Buy15.3215,197232,7542,615,970Nov 19 08:15 PM